Data from EMC - Curated by Toby Galbraith - Last updated 21 April 2017

Licensing authority

EMA (European Medicines Agency)

Indication(s)

Jylamvo is for use in the following indications:

In rheumatological and dermatological diseases
- Active rheumatoid arthritis in adult patients.
- Polyarthritic forms of active, severe juvenile idiopathic arthritis (JIA) in adolescents and children aged 3 years and over when the response to non-steroidal anti-inflammatory drugs (NSAIDs) has been inadequate.
- Severe, treatment-refractory, disabling psoriasis which does not respond sufficiently to other forms of treatment such as phototherapy, psoralen and ultraviolet A radiation (PUVA) therapy and retinoids, and severe psoriatic arthritis in adult patients.

In oncology
- Maintenance treatment of acute lymphoblastic leukaemia (ALL) in adults, adolescents and children aged 3 years and over.

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Chronic Lymphocytic Leukaemia (CLL)

Refine your knowledge of chronic lymphocytic leukaemia (CLL) with information on pathophysiology, diagnosis, treatment options and more

Visit Chronic Lymphocytic Leukaemia (CLL)

Psoriasis

See information on psoriasis pathophysiology, signs and symptoms, comorbidities, treatment options, and more

Visit Psoriasis

More information

Category Value
Agency product number EMEA/H/C/003756
Orphan designation No
Date First Approved 29-03-2017
Type Medicinal product subject to restricted medical prescription
Marketing authorisation holder Therakind Limited

Related Content